This nuclear energy stock has more than tripled over the past year. HSBC sees more gains ahead

HSBC initiated Oklo with a buy rating and a $96 price target, implying 32.6% upside from Wednesday's close. The bank cited Oklo's selection for four DOE pilot projects, an accelerated licensing timeline, and first revenue expected later this year from the Idaho Radiochemistry Laboratory. HSBC also highlighted a clean balance sheet, customer pre-payments, third-party investment support, and long-term financing options that could fund capex and support growth.

Analysis

The key incremental signal is not the coverage initiation itself, but that Oklo is moving from a pure story stock toward a quasi-policy-enabled industrial platform. The federal pilot framework materially lowers the probability of a prolonged permitting deadlock, which should compress the discount rate investors apply to first revenue and subsequent site replication. That matters because in pre-scale nuclear, the market is valuing execution optionality more than current earnings; any credible path to repeatable licensing can re-rate the entire small modular reactor peer set.

Second-order beneficiaries are less obvious: domestic nuclear fuel services, specialty fabrication, and radiochemistry vendors gain from a policy regime that favors localized supply chains. By contrast, utilities and independent power producers pursuing conventional baseload buildouts may face a higher hurdle rate if capital starts rotating toward “approved” advanced nuclear projects with federal validation. Meta is also indirectly signaled as a more committed buyer of firm power, which supports the broader data-center power procurement trade and could lift other behind-the-meter nuclear or geothermal concepts.

The main risk is that the stock is already pricing a lot of execution. The gap between pilot approval and commercial-scale deployment is still measured in years, and any slippage on criticality, cost overruns, or financing terms would hit hard because the equity is effectively a long-duration call option on regulatory success. Near term, the catalyst stack is binary: first revenue later this year, milestone updates into mid-2026, and any additional federal funding or loan support over the next 6-18 months.

Consensus looks directionally right but may be underestimating how much of the upside depends on capital structure rather than reactor physics. If financing remains mostly equity-funded, dilution could cap returns even with good operational progress; if debt and customer prepayments scale, the stock can keep compounding. The market may also be underpricing the chance that federal support creates a winner-take-most dynamic in advanced nuclear, leaving lagging peers stranded without comparable policy access.

Key Decisions for Investors

• Maintain a tactical long OKLO, but size it as a high-volatility execution trade rather than a core fundamental holding; best entry is on post-rally pullbacks or after any milestone-driven consolidation over the next 2-6 weeks.
• Express a relative-value view: long OKLO / short a basket of pre-revenue clean-tech incumbents with weaker policy access, targeting 3-6 month dispersion if the DOE pathway continues to de-risk licensing.
• Buy OKLO call spreads expiring after the first revenue print and ahead of mid-2026 milestone windows; the risk/reward is attractive if the market continues to price in milestone progression but not full commercialization.
• If already long, hedge with puts into any headline surge above prior highs; the stock’s long-duration profile makes it vulnerable to sharp drawdowns on one missed timeline or financing update.
• For portfolio construction, pair any OKLO exposure with beneficiaries of firm-power demand such as utility infrastructure or grid equipment names rather than broad clean-energy beta.